CYCLOSPORIN A
DNA Damage Repair Deficiency
Virginia G. Kaklamaniprotein_peptideEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the DNA Damage Repair Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atezolizumab National Cancer Institute (NCI) | Phase 3 | B |
Eloxatin National Cancer Institute (NCI) | Phase 3 | B |
FLUOROURACILUM National Cancer Institute (NCI) | Phase 3 | B |
Niraparib University of California, Davis | Phase 2 | CCC |
Docetaxel The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
CYCLOSPORIN A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →